1. Home
  2. EARN vs GBIO Comparison

EARN vs GBIO Comparison

Compare EARN & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$5.32

Market Cap

189.7M

Sector

Real Estate

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.41

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EARN
GBIO
Founded
2012
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
189.7M
36.3M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
EARN
GBIO
Price
$5.32
$5.41
Analyst Decision
Buy
Buy
Analyst Count
2
5
Target Price
$5.88
$8.88
AVG Volume (30 Days)
323.8K
61.5K
Earning Date
02-20-2026
11-05-2025
Dividend Yield
18.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,893,000.00
$15,270,000.00
Revenue This Year
$8.43
N/A
Revenue Next Year
$17.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
43.30
N/A
52 Week Low
$4.33
$3.00
52 Week High
$6.86
$12.50

Technical Indicators

Market Signals
Indicator
EARN
GBIO
Relative Strength Index (RSI) 52.63 55.34
Support Level $5.10 $5.20
Resistance Level $5.20 $5.54
Average True Range (ATR) 0.10 0.24
MACD -0.00 0.04
Stochastic Oscillator 60.18 79.66

Price Performance

Historical Comparison
EARN
GBIO

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: